CN107530373B - 用于在患者中口服施用的含有砷的高表面积冻干组合物 - Google Patents
用于在患者中口服施用的含有砷的高表面积冻干组合物 Download PDFInfo
- Publication number
- CN107530373B CN107530373B CN201680020478.8A CN201680020478A CN107530373B CN 107530373 B CN107530373 B CN 107530373B CN 201680020478 A CN201680020478 A CN 201680020478A CN 107530373 B CN107530373 B CN 107530373B
- Authority
- CN
- China
- Prior art keywords
- minutes
- powder
- pharmaceutical composition
- product
- mtorr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311663020.2A CN117899029A (zh) | 2015-02-01 | 2016-02-01 | 用于在患者中口服施用的含有砷的高表面积冻干组合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110574P | 2015-02-01 | 2015-02-01 | |
| US62/110574 | 2015-02-01 | ||
| US201562142709P | 2015-04-03 | 2015-04-03 | |
| US62/142709 | 2015-04-03 | ||
| PCT/US2016/015917 WO2016123603A2 (en) | 2015-02-01 | 2016-02-01 | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311663020.2A Division CN117899029A (zh) | 2015-02-01 | 2016-02-01 | 用于在患者中口服施用的含有砷的高表面积冻干组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107530373A CN107530373A (zh) | 2018-01-02 |
| CN107530373B true CN107530373B (zh) | 2023-12-29 |
Family
ID=56544541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680020478.8A Active CN107530373B (zh) | 2015-02-01 | 2016-02-01 | 用于在患者中口服施用的含有砷的高表面积冻干组合物 |
| CN202311663020.2A Pending CN117899029A (zh) | 2015-02-01 | 2016-02-01 | 用于在患者中口服施用的含有砷的高表面积冻干组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311663020.2A Pending CN117899029A (zh) | 2015-02-01 | 2016-02-01 | 用于在患者中口服施用的含有砷的高表面积冻干组合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10111836B2 (enExample) |
| EP (3) | EP3981414B1 (enExample) |
| JP (3) | JP6928768B2 (enExample) |
| CN (2) | CN107530373B (enExample) |
| AU (4) | AU2016211186A1 (enExample) |
| CA (2) | CA2975406C (enExample) |
| DK (1) | DK3981414T3 (enExample) |
| ES (2) | ES3034734T3 (enExample) |
| FI (1) | FI3981414T3 (enExample) |
| HR (1) | HRP20251032T1 (enExample) |
| HU (1) | HUE072537T2 (enExample) |
| LT (1) | LT3981414T (enExample) |
| MX (2) | MX390835B (enExample) |
| PL (1) | PL3981414T3 (enExample) |
| PT (1) | PT3981414T (enExample) |
| RS (1) | RS67133B1 (enExample) |
| SI (1) | SI3981414T1 (enExample) |
| SM (1) | SMT202500321T1 (enExample) |
| TW (3) | TWI790191B (enExample) |
| WO (1) | WO2016123603A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2975406C (en) | 2015-02-01 | 2025-07-22 | Quetzal Therapeutics, Llc | LYOPHILIZED COMPOSITIONS WITH HIGH SPECIFIC SURFACE AREA CONTAINING ARSENIC INTENDED FOR ORAL ADMINISTRATION IN PATIENTS |
| US20260027056A1 (en) * | 2015-02-01 | 2026-01-29 | Quetzal Therapeutics, Llc | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
| AU2017368444B9 (en) | 2016-12-01 | 2020-07-02 | Eupharma Pty Ltd | Arsenic compositions |
| KR101844049B1 (ko) | 2016-12-05 | 2018-03-30 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물 |
| KR101844050B1 (ko) * | 2016-12-09 | 2018-05-14 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물 |
| US20190374611A1 (en) * | 2017-01-18 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders |
| US12582984B1 (en) | 2020-07-02 | 2026-03-24 | Argonaut Manufacturing Services, Inc. | Method for lyophilization and device thereof |
| US11583552B2 (en) | 2021-02-17 | 2023-02-21 | Manoj Maniar | Pharmaceutical formulation of arsenic trioxide |
| JP7428842B1 (ja) | 2023-03-29 | 2024-02-06 | ａｒｔｉｅｎｃｅ株式会社 | 活性エネルギー線硬化型インキ、その製造方法、および印刷物 |
| AU2025223378A1 (en) * | 2024-02-14 | 2026-07-30 | Assistance Publique - Hôpitaux De Paris | Oral composition of arsenic trioxide for cancer treatment |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040126434A1 (en) * | 2002-10-09 | 2004-07-01 | Kumana Cyrus Rustam | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| CN103142648A (zh) * | 2011-12-07 | 2013-06-12 | 浙江中医药大学 | 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773419A (en) | 1995-03-03 | 1998-06-30 | Falcon; Juan | Method of treating cancer with tannic acid |
| CN1044559C (zh) | 1995-08-23 | 1999-08-11 | 哈尔滨医科大学附属第一医院 | 抗白血病、肝癌、淋巴瘤注射液 |
| IL136051A0 (en) | 1997-11-10 | 2001-05-20 | Sloan Kettering Inst Cancer | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| US7276359B1 (en) * | 1998-03-13 | 2007-10-02 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
| CN1131922C (zh) | 1998-10-19 | 2003-12-24 | 张在喆 | 一种通过弹性键搭架与收拢的帐篷 |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| CN102772413A (zh) * | 2000-02-29 | 2012-11-14 | 布里斯托尔-迈尔斯斯奎布公司 | 低剂量艾替开韦制剂及其应用 |
| AUPR874601A0 (en) * | 2001-11-08 | 2001-11-29 | Unisearch Limited | Selective targeting of apoptotic cells |
| US8906422B2 (en) | 2002-10-09 | 2014-12-09 | The University Of Hong Kong | Method for inhibiting cancer using arsenic trioxide |
| GB0315632D0 (en) * | 2003-07-04 | 2003-08-13 | West Pharm Serv Drug Res Ltd | Pharmaceutical formulations |
| CN1251688C (zh) | 2003-12-09 | 2006-04-19 | 重庆维特瑞医药开发有限公司 | 三氧化二砷冻干粉针及其生产方法 |
| JP4292985B2 (ja) | 2003-12-25 | 2009-07-08 | Ｊｓｒ株式会社 | 感放射線性組成物、マイクロレンズとその形成方法および液晶表示素子 |
| CN1698650A (zh) | 2004-05-21 | 2005-11-23 | 哈尔滨伊达药业有限公司 | 一种治疗原发性肝癌的亚砷酸注射液及其制备方法 |
| CN1326528C (zh) | 2004-07-13 | 2007-07-18 | 东南大学 | 砒霜磁性纳米明胶微球的制备工艺 |
| EA015781B1 (ru) | 2005-10-21 | 2011-12-30 | Панацея Биотек Лимитед | Композиции для лечения рака |
| US20080089951A1 (en) * | 2006-10-11 | 2008-04-17 | The University Of Hong Kong | Method for Inhibiting Cancer Using Arsenic Trioxide |
| CN101322719B (zh) | 2007-06-15 | 2012-03-07 | 杭州民生药业有限公司 | 一种三氧化二砷固体脂质纳米粒及其制剂 |
| US8168224B2 (en) * | 2007-12-19 | 2012-05-01 | Beijing Shengyiyao Science & Technology Development Co., Ltd. | Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof |
| US20110165259A1 (en) | 2008-09-19 | 2011-07-07 | Activus Pharma Co., Ltd. | Composite organic compound powder for medical use, method for producing same and suspension of same |
| EP2359812A1 (en) | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
| EP2525783A1 (en) | 2010-01-18 | 2012-11-28 | Cephalon France | Improved oral lysophilisates containing pvp/va |
| CN103408477B (zh) | 2013-08-22 | 2015-06-10 | 陈鹏飞 | 一种含砷配位化合物及其制备方法 |
| PL3250213T3 (pl) | 2015-01-29 | 2023-10-30 | Eupharma Pty Ltd | Kompozycje zawierające arsen do stosowania w sposobach leczenia |
| CA2975406C (en) | 2015-02-01 | 2025-07-22 | Quetzal Therapeutics, Llc | LYOPHILIZED COMPOSITIONS WITH HIGH SPECIFIC SURFACE AREA CONTAINING ARSENIC INTENDED FOR ORAL ADMINISTRATION IN PATIENTS |
-
2016
- 2016-02-01 CA CA2975406A patent/CA2975406C/en active Active
- 2016-02-01 MX MX2017009913A patent/MX390835B/es unknown
- 2016-02-01 SM SM20250321T patent/SMT202500321T1/it unknown
- 2016-02-01 SI SI201631917T patent/SI3981414T1/sl unknown
- 2016-02-01 RS RS20250815A patent/RS67133B1/sr unknown
- 2016-02-01 TW TW105103175A patent/TWI790191B/zh active
- 2016-02-01 TW TW111149127A patent/TW202337477A/zh unknown
- 2016-02-01 CN CN201680020478.8A patent/CN107530373B/zh active Active
- 2016-02-01 PT PT211925946T patent/PT3981414T/pt unknown
- 2016-02-01 CN CN202311663020.2A patent/CN117899029A/zh active Pending
- 2016-02-01 EP EP21192594.6A patent/EP3981414B1/en active Active
- 2016-02-01 CA CA3225480A patent/CA3225480A1/en active Pending
- 2016-02-01 US US15/012,355 patent/US10111836B2/en active Active
- 2016-02-01 WO PCT/US2016/015917 patent/WO2016123603A2/en not_active Ceased
- 2016-02-01 EP EP25184422.1A patent/EP4599823A1/en active Pending
- 2016-02-01 DK DK21192594.6T patent/DK3981414T3/da active
- 2016-02-01 HR HRP20251032TT patent/HRP20251032T1/hr unknown
- 2016-02-01 ES ES21192594T patent/ES3034734T3/es active Active
- 2016-02-01 TW TW110142380A patent/TW202228734A/zh unknown
- 2016-02-01 JP JP2017559275A patent/JP6928768B2/ja active Active
- 2016-02-01 FI FIEP21192594.6T patent/FI3981414T3/fi active
- 2016-02-01 AU AU2016211186A patent/AU2016211186A1/en not_active Abandoned
- 2016-02-01 EP EP16744263.1A patent/EP3250214B1/en active Active
- 2016-02-01 ES ES16744263T patent/ES2899226T3/es active Active
- 2016-02-01 HU HUE21192594A patent/HUE072537T2/hu unknown
- 2016-02-01 PL PL21192594.6T patent/PL3981414T3/pl unknown
- 2016-02-01 LT LTEP21192594.6T patent/LT3981414T/lt unknown
-
2017
- 2017-07-31 MX MX2020012611A patent/MX2020012611A/es unknown
-
2018
- 2018-10-01 US US16/148,193 patent/US10272045B2/en active Active
-
2019
- 2019-03-12 US US16/299,214 patent/US10653628B2/en active Active
-
2020
- 2020-04-20 US US16/852,758 patent/US20210069115A1/en not_active Abandoned
-
2021
- 2021-06-07 AU AU2021203752A patent/AU2021203752B2/en active Active
- 2021-06-22 JP JP2021103196A patent/JP7539855B2/ja active Active
-
2023
- 2023-01-27 US US18/160,445 patent/US12364664B2/en active Active
- 2023-08-10 AU AU2023214307A patent/AU2023214307B2/en active Active
-
2024
- 2024-01-10 US US18/408,664 patent/US20240269076A1/en active Pending
- 2024-08-14 JP JP2024135193A patent/JP7885288B2/ja active Active
-
2025
- 2025-10-29 AU AU2025259861A patent/AU2025259861A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040126434A1 (en) * | 2002-10-09 | 2004-07-01 | Kumana Cyrus Rustam | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| CN103142648A (zh) * | 2011-12-07 | 2013-06-12 | 浙江中医药大学 | 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021203752B2 (en) | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | |
| CN113853374A (zh) | 具有增强的生物利用度的化合物形式及其制剂 | |
| KR20210008527A (ko) | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물 및 이의 사용 방법 | |
| US11304898B2 (en) | Method of treating carcinoma | |
| CN114126660A (zh) | 药物复合物及其制备方法和用途 | |
| US20260027056A1 (en) | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | |
| HK40129981A (en) | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | |
| HK40073108A (en) | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | |
| HK1248113B (en) | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1248113 Country of ref document: HK |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201217 Address after: Georgia, USA Applicant after: Ausenix Co.,Ltd. Address before: Delaware, USA Applicant before: Orsenix Holdings B.V. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20250909 Address after: Massachusetts, USA Patentee after: SYROS PHARMACEUTICALS, Inc. Country or region after: U.S.A. Address before: Georgia, USA Patentee before: Ausenix Co.,Ltd. Country or region before: U.S.A. Effective date of registration: 20250910 Address after: Illinois, USA Patentee after: Gechal Treatment Limited Liability Company Country or region after: U.S.A. Address before: Massachusetts, USA Patentee before: SYROS PHARMACEUTICALS, Inc. Country or region before: U.S.A. |